<DOC>
	<DOCNO>NCT00003359</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness T138067 sodium treat patient advanced refractory cancer .</brief_summary>
	<brief_title>T138067 Sodium Treating Patients With Advanced Refractory Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose T138067 sodium give patient advanced refractory cancer 28-day schedule establish dose study . II . Evaluate safety dose limit toxicity T138067 sodium patient . III . Determine pharmacokinetic parameter single intravenous dose agent patient . IV . Obtain safety data preliminary efficacy information repetition single dos T138067 sodium patient . OUTLINE : This open label , dose escalation study . Patients receive T138067 sodium IV 3 hour . Patients may retreat every 4 week 6 course ( 6 month total ) absence disease progression dose limit toxicity ( DLT ) . At least 3 patient treat dose level absence DLT . The maximum tolerate dose define dose level 2 3-6 patient experience DLT . PROJECTED ACCRUAL : Approximately 3-24 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced refractory cancer Must meet one follow criterion : Failed least 1 regimen radiotherapy , chemotherapy , immunotherapy candidate regimen higher efficacy Refractory exist standard therapy candidate regimen higher efficacy Advanced malignancy standard chemotherapy available No known brain metastasis leptomeningeal involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Greater 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Prothrombin time least 30 % control Partial thromboplastin time least 30 % control Hepatic : Bilirubin le 2 mg/dL ALT AST great 2 time normal Alkaline phosphatase great 2 time normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No New York Heart Association class III IV heart disease No myocardial infarction past 6 month Other : No immunodeficiency syndrome ( acquire congenital ) No uncontrolled infection No significant comorbidity may compromise participation study Not pregnant Effective contraception require fertile patient 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 4 week since prior immunotherapy No concurrent immunotherapy biologic response modifier therapy Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroid Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : At least 3 week since prior major surgery Other : No organ allograft At least 30 day since prior investigational agent No concurrent nonsteroidal antiinflammatory agent aspirin No concurrent alternative therapy ( i.e. , herbal medicine , high dos vitamin ) No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>